160 related articles for article (PubMed ID: 11781641)
1. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation.
Balasubramanian P; Chandy M; Krishnamoorthy R; Srivastava A
Bone Marrow Transplant; 2001 Nov; 28(9):821-5. PubMed ID: 11781641
[TBL] [Abstract][Full Text] [Related]
2. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
3. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.
Chattergoon DS; Saunders EF; Klein J; Calderwood S; Doyle J; Freedman MH; Koren G
Bone Marrow Transplant; 1997 Sep; 20(5):347-54. PubMed ID: 9339748
[TBL] [Abstract][Full Text] [Related]
4. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia.
Pawlowska AB; Blazar BR; Angelucci E; Baronciani D; Shu XO; Bostrom B
Bone Marrow Transplant; 1997 Dec; 20(11):915-20. PubMed ID: 9422469
[TBL] [Abstract][Full Text] [Related]
5. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.
Bertholle-Bonnet V; Bleyzac N; Galambrun C; Mialou V; Bertrand Y; Souillet G; Aulagner G
Ther Drug Monit; 2007 Apr; 29(2):177-84. PubMed ID: 17417071
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation.
Poonkuzhali B; Srivastava A; Quernin MH; Dennison D; Aigrain EJ; Kanagasabapathy AS; Krishnamoorthy R; Chandy M
Bone Marrow Transplant; 1999 Jul; 24(1):5-11. PubMed ID: 10435727
[TBL] [Abstract][Full Text] [Related]
7. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation.
Poonkuzhali B; Chandy M; Srivastava A; Dennison D; Krishnamoorthy R
Drug Metab Dispos; 2001 Mar; 29(3):264-7. PubMed ID: 11181493
[TBL] [Abstract][Full Text] [Related]
8. Retrospective appraisal of busulfan dose adjustment in children.
Dupuis LL; Najdova M; Saunders EF
Bone Marrow Transplant; 2000 Dec; 26(11):1143-7. PubMed ID: 11149723
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome.
Chandy M; Balasubramanian P; Ramachandran SV; Mathews V; George B; Dennison D; Krishnamoorthy R; Srivastava A
Bone Marrow Transplant; 2005 Nov; 36(10):839-45. PubMed ID: 16151422
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of busulfan area under the curve: estimation by a single measurement.
Tabak A; Hoffer E; Rowe JM; Krivoy N
Ther Drug Monit; 2001 Oct; 23(5):526-8. PubMed ID: 11591898
[TBL] [Abstract][Full Text] [Related]
12. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
Dupuis LL; Sibbald C; Schechter T; Ansari M; Gassas A; Théorêt Y; Kassir N; Champagne MA; Doyle J
Biol Blood Marrow Transplant; 2008 May; 14(5):576-82. PubMed ID: 18410900
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
[TBL] [Abstract][Full Text] [Related]
14. Busulphan level and early mortality in thalassaemia patients after BMT.
Li CK; Yuen PM; Wong R; Pang CP; Lai WK; Law E; Shing MM; Chik KW; Leung TF
Bone Marrow Transplant; 1999 Feb; 23(4):307-10. PubMed ID: 10100572
[TBL] [Abstract][Full Text] [Related]
15. Busulfan systemic exposure after oral administration of extemporeanously prepared high-dose busulfan capsules.
Kolbe K; Karstens A; Krämer I
J Oncol Pharm Pract; 2010 Sep; 16(3):151-9. PubMed ID: 19759052
[TBL] [Abstract][Full Text] [Related]
16. Predictive performance of a physiologically based pharmacokinetic model of busulfan in children.
Diestelhorst C; Boos J; McCune JS; Russell J; Kangarloo SB; Hempel G
Pediatr Hematol Oncol; 2014 Nov; 31(8):731-42. PubMed ID: 25007236
[TBL] [Abstract][Full Text] [Related]
17. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
[TBL] [Abstract][Full Text] [Related]
20. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation.
Copelan EA; Bechtel TP; Avalos BR; Elder PJ; Ezzone SA; Scholl MD; Penza SL
Bone Marrow Transplant; 2001 Jun; 27(11):1121-4. PubMed ID: 11551021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]